Stay updated on Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Removed sponsor branding and related links (e.g., Merck Clinical Trials Information and Merck Sharp & Dohme LLC) along with IPD sharing details and drug/MeSH terms from the page. This changes cosmetic/auxiliary content without altering core study information such as study design, treatment arms, outcomes, or eligibility.
    Difference
    19%
    Check dated 2026-01-21T02:48:41.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Revision: v3.3.4 replaces the previous v3.3.3 label.
    Difference
    0.1%
    Check dated 2026-01-14T01:49:20.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    Revision: v3.3.3 is now displayed in the footer. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed.
    Difference
    0.1%
    Check dated 2025-12-23T13:31:16.000Z thumbnail image
  5. Check
    60 days ago
    Change Detected
    Summary
    Publication notes were updated to state that publications are automatically filled from PubMed and may not always pertain to the study, replacing the previous longer description. The page revision tag was updated to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-24T17:54:45.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    A notice about potential data delays due to government funding lapses and the NIH Clinical Center's operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T17:46:15.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Results from KEYNOTE-040 are now displayed, including OS, PFS, ORR, DOR, and safety outcomes. The new content provides outcome data for pembrolizumab versus standard treatment in recurrent/metastatic head and neck cancer.
    Difference
    0.4%
    Check dated 2025-11-03T12:35:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Treatment in Head and Neck Cancer Clinical Trial page.